$Avita Medical (RCEL.US)$ AVITA Medical Announces FDA Approval of RECELL GO AVITA Medical announced FDA approval for its advanced autologous cell harvesting device, RECELL GO. This next-gen device improves treatment for thermal burn wounds and full-thickness skin defects by harnessing a patient's own skin. Key advantages include faster healing, reduced pain, improved aesthetics, and fewer procedures. Enhanced features streamline the preparation of Spray-On Skin Cells and improve workflow effi...
Avita Medical股票討論
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical announced FDA approval for its advanced autologous cell harvesting device, RECELL GO. This next-gen device improves treatment for thermal burn wounds and full-thickness skin defects by harnessing a patient's own skin. Key advantages include faster healing, reduced pain, improved aesthetics, and fewer procedures. Enhanced features streamline the preparation of Spray-On Skin Cells and improve workflow effi...
對收入/指引的反應:
• $Planet Labs PBC (PL.US)$ 升百分之十一點三, $Core & Main (CNM.US)$ 增加百分之六點一, $Regal Rexnord (RRX.US)$ +2%(重新確認展望), $甲骨文 (ORCL.US)$ +1.6%
其他新聞:
• $Akero Therapeutics (AKRO.US)$ 增加 93.2%(報告第二階段和諧研究)
• $Akouos (AKUS.US)$ 增加 10.3%(FDA 通過 IND 申請,首次在人類兒科臨床試驗 AK-OTOF 的人類兒科臨床試驗中開始 1/2 階段)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
對收入/指引的反應:
• $Wolfspeed (WOLF.US)$ 增加 22.2%, $阿特斯太陽能 (CSIQ.US)$ 增加 6.5%, $BJ批發俱樂部 (BJ.US)$ 增加 5.8%, $思科 (CSCO.US)$ 增加 5.3%, $Keysight Technologies (KEYS.US)$ 增加百分之四點三 $麥迪森運動 (MSGS.US)$ 增加 3%, $網易 (NTES.US)$ 增加百分之二點七, $NICE Ltd (NICE.US)$ 增加 2.1%, $新思科技 (SNPS.US)$ + 1.8%
最新消息:
• $Brooge Energy (BROG.US)$ +17.1%(表示,BPGIC 控股的主要股東希望獲得...
對收入/指引的反應:
• $Payoneer Global (PAYO.US)$ 升百分之十九點四, $Toast (TOST.US)$ 升百分之十三點一, $PDF Solutions (PDFS.US)$ 增加 7.7% $Wheels Up Experience (UP.US)$ 增加 7.1%, $LegalZoom (LZ.US)$ 增加 6.5%, $Joby Aviation (JOBY.US)$ 增加 3.6%, $indie Semiconductor (INDI.US)$ 升百分之二點九, $Rocket Lab (RKLB.US)$ 增加 2.4%, $Rivian Automotive (RIVN.US)$ +1.2%
其他新聞:
• $悅商集團 (WETG.US)$ 增加 47.8%(宣布向公司銷售五百萬美元的猴子花病毒測試套件)
暫無評論